Table 4.
Description of Major Bleeds (N=45)
| Descriptor | N (%) |
|---|---|
| INR (N=34) | |
| Median (range)* | 3.5 (1.3–16.3) |
| Subtherapeutic | 6 (17.6) |
| Therapeutic | 9 (26.5) |
| Supratherapeutic | 19 (55.9) |
| Location of hemorrhage | |
| GI | 26 (57.8) |
| HEENT | 7 (15.6) |
| Soft tissue | 4 (8.9) |
| CNS | 4 (8.9) |
| GU | 2 (4.4) |
| Unknown† | 2 (4.4) |
| Duration of warfarin therapy prior to bleed‡ | |
| <1 mo | 3 (7.1) |
| ≥1 mo to <1 y | 9 (21.4) |
| ≥1 to<3 y | 13 (31.0) |
| ≥3 y | 17 (40.5) |
| Outcomes | |
| Bleed resolved–warfarin continued | 16 (35.6) |
| Bleed resolved–warfarin discontinued | 29 (64.4) |
| Death | 0 |
*
INRs were unavailable for 11 patients who presented to a facility outside of the VA
†
These patients were hospitalized outside of the VA and required a transfusion, but records were unavailable to identify the source of the major bleed
‡
Forty-five major bleeds occurred in 42 patients
HEENT, head, eyes, ears, nose, and throat (e.g., epistaxis, hemoptysis); CNS, central nervous system (e.g., subdural, intracranial); GU, genitourinary tract